Findings

What do systematic reviews say?

5 questions · 5 findings · 5 reviews · Schizophrenia

No studies found 0 · 0%GRADE not reported 1 · 20%Very low 0 · 0%Low 2 · 40%Moderate 2 · 40%High 0 · 0%

Response to treatment · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Response to treatment · patients with schizophrenia

FLUPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).

1 finding from 1 review

Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.03 [0.73, 1.45]
2 studies · 103 participants
Moderate

Response to treatment · patients with schizophrenia

Comparison 1: PERPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).

1 finding from 1 review

Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.97 [0.74, 1.26]
2 studies · 138 participants
Moderate

Clinical response to treatment · patients with schizophrenia

HALOPERIDOL showed no clear difference in clinical response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.11 [0.86, 1.44]
14 studies · 574 participants
Low

Response to treatment ‐ medium term · patients with schizophrenia

Trifluoperazine showed no clear difference in response to treatment ‐ medium term compared with low‐potency antipsychotic drugs (low certainty).

1 finding from 1 review

Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.96 [0.59, 1.56]
3 studies · 120 participants
Low